1-cyclopropyl-2-(2-fluorophenyl)ethanone CAS 150322-73-9

Product Description:

Product Name: 1-cyclopropyl-2-(2-fluorophenyl)ethanone CAS NO:150322-73-9

Synonyms:

Cyclopropyl-2-fluoro benzyl ketone;

Ethanone, 1-cyclopropyl-2-(2-fluorophenyl)-;

Chemical & Physical Properties:

Appearance : Pale Yellow Oil

Assay :≥99.0%

Density:1.192 g/cm3

Boiling Point:253.6℃ at 760 mmHg

Flash Point:107.9℃

1-cyclopropyl-2-(2-fluorophenyl)ethanone is used to prasugrel intermediate.

Prasugrel is a thienopyridine antiplatelet drug developed by Eli Lilly and Japanese pharmaceutical manufacturer Daiichi Sankyo (Daiichi Sankyo). It is a prodrug that is metabolized by cytochrome P450 in the liver to form an active molecule. Platelet P2Y12 receptor binds to exert anti-platelet aggregation activity.

On December 18, 2008, Prasugrel received its first important international recognition. The European Medicines Board's European Committee for Medical Products (CHMP) recommended approval of the drug. In late February 2009, it was approved by the European Commission.

In Europe, it is sold under the trade name Efient and is used to treat acute coronary syndrome. Prasugrel works by blocking P2Y12 adenosine diphosphate receptors on the platelet surface to inhibit platelet activation and concurrent aggregation. Antiplatelet drugs are used to prevent platelet aggregation or sticking together. If platelet aggregation causes arterial blockage and may cause heart disease or stroke.

On July 10, 2009, the US Food and Drug Administration approved prasugrel tablets for patients undergoing angioplasty to reduce the risk of thrombosis.

It was approved in Canada in April 2010 for the treatment of acute coronary syndrome.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.